Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/09/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/24/2023 | 83.69% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/03/2023 | 83.69% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 11/08/2022 | 32.26% | Goldman Sachs | $13 → $18 | Maintains | Neutral |
| 08/16/2022 | -4.48% | Goldman Sachs | $10 → $13 | Maintains | Neutral |
| 05/24/2022 | -26.52% | Goldman Sachs | $22 → $10 | Maintains | Neutral |
| 11/24/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/23/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 113.08% | Goldman Sachs | → $29 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 08/09/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 08/02/2023 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 2023年05月24日 | 83.69% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 04/03/2023 | 83.69% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 11/08/2022 | 32.26% | 高盛 | $13→$18 | 維護 | 中性 |
| 08/16/2022 | -4.48% | 高盛 | $10→$13 | 維護 | 中性 |
| 2022年05月24日 | -26.52% | 高盛 | $22→$10 | 維護 | 中性 |
| 2021年11月24日 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2021年11月23日 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2021年11月23日 | 113.08% | 高盛 | →$29 | 開始承保 | →中性 |
What is the target price for Entrada Therapeutics (TRDA)?
Entrada治療公司(TRDA)的目標價格是多少？
The latest price target for Entrada Therapeutics (NASDAQ: TRDA) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $25.00 expecting TRDA to rise to within 12 months (a possible 83.69% upside). 6 analyst firms have reported ratings in the last year.
恩特拉達治療公司(納斯達克代碼：TRDA)的最新目標價是由HC Wainwright&Co.於2023年9月22日報道的。這家分析公司將目標價定為25.00美元，預計TRDA將在12個月內升至(可能上漲83.69%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
Entrada治療公司(TRDA)的最新分析師評級是多少？
The latest analyst rating for Entrada Therapeutics (NASDAQ: TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics reiterated their buy rating.
恩特拉達治療公司(納斯達克代碼：TRDA)的最新分析師評級由HC Wainwright&Co.提供，恩特拉達治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Entrada治療公司(TRDA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Entrada治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Entrada治療公司的上一次評級是在2023年9月22日提交的，因此您應該預計下一次評級將在2024年9月22日左右提供。
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
分析師對Entrada Treeutics(TRDA)的評級正確嗎？
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a reiterated with a price target of $0.00 to $25.00. The current price Entrada Therapeutics (TRDA) is trading at is $13.61, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Entrada治療公司(TRDA)評級被重申，目標價在0.00美元至25.00美元之間。Entrada治療公司(TRDA)目前的交易價格為13.61美元，在分析師的預測範圍內。